Merck
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
Merck Discontinues TIGIT and LAG-3 Programs Amid Efficacy Concerns
Merck, TIGIT, LAG-3, Keytruda, Cancer Therapy, Clinical Trials
Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates
Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality
Merck’s Subcutaneous Keytruda Shows Non-Inferiority in Phase 3 Trial, Paving Way for Regulatory Discussions
Merck, Keytruda, subcutaneous, cancer immunotherapy, phase 3 trial, non-inferiority, regulatory submissions
Merck’s Gardasil Sales in China Continue to Decline Amid Economic and Regulatory Challenges
Merck, Gardasil, China, vaccine sales, economic challenges, regulatory issues
Merck Reports Strong Q3 Results but Lowers Full-Year Sales Guidance
Merck, Q3 Results, Full-Year Sales Guidance, Keytruda, Gardasil, Januvia, Winrevair, Capvaxive
Merck Acquires “Chameleon” Approach to Combat Deadly Brain Cancers for $30 Million
Merck, brain cancer, chameleon approach, $30 million, pharmaceutical acquisition
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers
Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630